Compare · DFTX vs XXII
DFTX vs XXII
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and 22nd Century Group Inc. (XXII): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and XXII operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 13.9x XXII ($332.0M).
- DFTX has been more active in the news (11 items in the past 4 weeks vs 3 for XXII).
- DFTX has more recent analyst coverage (8 ratings vs 4 for XXII).
- Company
- Definium Therapeutics Inc.
- 22nd Century Group Inc.
- Price
- -
- -
- Market cap
- $4.60B
- $332.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- AMEX
- IPO
- News (4w)
- 11
- 3
- Recent ratings
- 8
- 4
22nd Century Group Inc.
22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest XXII
- 22nd Century Same Store Unit Sales for Pinnacle VLN® and Pinnacle Pure Surge 161%
- 22nd Century Group's Reduced-Nicotine Tobacco Platform Positioned to Support France's Nicotine-Reduction Initiative
- 22nd Century Group Urges Policymakers and FDA to Enact and Implement the Reduced Nicotine Content Standard, Citing Years Without a Final Rule
- 22nd Century Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- 22nd Century CEO & Chairman Larry Firestone: Improved Gross Margin, ~5,000 Retail Outlets and >$50B Market Opportunity Highlight Mid-Year Stockholder Letter
- 22nd Century Group to Participate in the HC Wainwright Conference on September 15, 2026
- SEC Form S-8 filed by 22nd Century Group Inc.
- SEC Form 10-Q filed by 22nd Century Group Inc.
- 22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 22nd Century Group Reports Second Quarter 2026 Financial Results